NAD+

The presence of NAD+ in normal metabolism is a reason to investigate it, not proof that administering more improves health. A change in a blood marker is also not the same as a patient feeling or functioning better. Product-specific human evidence is needed.

FDA has warned compounders about using unsuitable dietary-grade NAD+ ingredients and has received adverse-event reports including severe chills, shaking and vomiting after injectable products. Ingredient sourcing and endotoxin contamination are material concerns, independent of whether a claimed wellness benefit is plausible. ¹

Identify the route, ingredient quality, pharmacy and intended clinical purpose. A patient-specific 503A preparation is compounded by a state-licensed 503A pharmacy pursuant to a patient-specific prescription; that does not make it FDA-approved or establish effectiveness for the proposed use. ²

NAD participates in cellular redox reactions and metabolism, but that biological role does not show that an intravenous or injectable NAD+ product improves energy, cognition, addiction recovery or aging. Oral, subcutaneous and intravenous exposure differ, and blood or tissue NAD measurements are not established patient-centered benefits. Claims need controlled human trials of the exact formulation, route, population and outcome rather than a pathway diagram or a report of transient sensations during an infusion. ^{1, 2}

FDA has described adverse events involving compounded NAD+ and has emphasized that compounded drugs are not reviewed for safety, effectiveness or quality before marketing. A bulk substance's interim compounding category is not approval. Ask which chemical form and grade are used, which pharmacy prepares the product, how sterility and endotoxin controls apply, and what the patient-specific reason is. A certificate of analysis does not establish clinical benefit or verify every prepared dose. ^{1, 2}

Rapid administration and the product itself may be associated with nausea, cramping, chest discomfort, headache or other symptoms. A clinic should have written monitoring and escalation procedures rather than treating distress as evidence that detoxification is working. Chest pain, breathing difficulty, fainting, severe allergic symptoms, fever after injection or neurologic change needs prompt medical assessment. Record the exact product, route, lot and infusion timing if an event occurs. Do not assume an unpleasant reaction demonstrates biological benefit. ^{1, 2}

Nicotinamide riboside and NMN are precursors studied as oral products; they are not equivalent to NAD+ infusion or injection. Evidence for a precursor cannot be transferred to intravenous NAD, and changes in NAD-related metabolites do not establish the same clinical outcome. If products are combined, document each one so adverse effects and laboratory changes are not attributed to whichever ingredient is most familiar. ^{1, 2}